Journal
ANTI-CANCER DRUGS
Volume 11, Issue 9, Pages 681-685Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001813-200010000-00002
Keywords
liposomal doxorubicin; metastatic breast cancer; paclitaxel
Categories
Ask authors/readers for more resources
The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure. Liposome-encapsulated doxorubicin is a new formulation of doxorubicin with no dose-limiting cardiac toxicity. Twenty-one patients with metastatic breast cancer were treated with pegylated liposomal doxorubicin (20 mg/m(2), day 1) and paclitaxel (100 mg/m(2), days 1 and 8) for six cycles every 2 weeks. All patients had had relapse or progression on one to five previous chemotherapies. We observed two patients with complete and eight patients with partial remissions (48% response rate). Eight of the 10 responders had had previous therapy with epirubicin, doxorubicin or mitoxantrone. The mean remission duration was 5 months. Disease progression due to brain metastasis occurred in five cases. Severe side effects (grade 3 WHO) were alopecia (100%), skin toxicity in 29%, neuropathy in 24% and mucositis in 13%. Leukopenia (grade 4 WHO) was observed in 48%, but there was no cardiac toxicity, no death and no hospitalization. The combination of weekly paclitaxel and liposomal doxorubicin every 2 weeks is highly effective in previously treated patients. Based on the doses we administered, we recommend 15 mg/m(2) liposomal doxorubicin every 2 weeks and 80 mg/m(2) paclitaxel weekly. [(C) 2000 Lippincott Williams 8 Wilkins].
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available